Implementation of simple point-of-care (POC) molecular assays for early infant HIV diagnosis (EID) and viral load (VL) quantification for early treatment failure identification can improve HIV monitoring in settings with limited laboratory infrastructure. However, they should be evaluated in areas with extremely high diversity of HIV-1 variants. We analyzed the efficacy of two POC techniques for EID and VL (Cepheid Xpert HIV-1 Quali and Xpert HIV-1 VL) versus the non-POC Roche CAP/CTM Quantitative test v2.0 in dried blood samples (DBS) collected from children and adults in Kinshasa (Democratic Republic of Congo, DRC), the epicenter of the group M epidemic.
From April to November of 2016, 163 DBS were collected in Monkole Hospital (Kinshasa, DRC) from 84 children (60 HIV-, 18 HIV+, 6 HIV-exposed) and 76 HIV-infected adults (66 treated, 10 naïve). HIV diagnosis was firstly performed in DRC using rapid serological tests. Using one dot, we confirmed HIV status in children (mean age 9.6 years) using Xpert Quali. We compared viraemia with Xpert VL and Roche in all HIV+, providing RNA-HIV-1 copies per dot and per plasma milliliter after considering patient´s hematocrit. HIV-1 variant was characterized by phylogeny in partial pol sequences.
HIV-1 infection was confirmed in 13 of 84 children by Xpert Qualy and in 71 (93.4%) of 76 adults by both Xpert VL and Roche VL, identifying false HIV+ diagnosis in DRC in 5 adults and in 5 children (range 12-158 months age), 4 of them under unnecessary ART during a mean time 35.6 months. Among the 84 HIV+ total samples, 80 (95.2%) could be detected by Xpert VL and 82 (97.6%) by Roche VL. Detectable viraemia with Xpert VL vs. Roche VL (>40 vs. >20 c/dot or >936-1078 vs. >468-539 c/ml plasma depending on hematocrit) was observed in 12 (92.3%) HIV+ children by both assays and in 53 (74.6%) or 52 (73.2%) HIV+ adults by Xpert or Roche, respectively. VL in 14/17 samples was below Xpert/Roche detection limit. A high correlation was observed among both VL assays (R2=0.91) but showing significant differences [≥0.5log, range from -0.55 to 1.07] in 12 (15.4%) of 78 cases with VL above detection limit by both assays. Most (91.7%) of 24 obtained HIV-1 sequences were unique recombinant forms (URF), with >1000 c/ml by both VL tests in all but one sample.
POC Xpert HIV-1 assays can successfully detect and quantify URF using DBS, which can improve the EID in HIV and of ART failures in countries with highly recombinants HIV-1 strains.